Loading…
← CockpitCompetitor Analysis › HNSA.ST Hansa Biopharma ABOpen in the cockpit ↗

Hansa Biopharma ABHNSA.STCompetitor analysis, valuation and peers

Sweden · SEK·Health Care›Pharmaceuticals: Major
Momentum leader 93
Mkt cap
$479M
US dollars, full cap
Free float
85%
of shares outstanding
$/day
$4.15M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 9.0%
Hurdle
-110 pp
Req g minus delivered
Next earnings
85 days
11 Feb 2027
Close · SEKSEK 47.88
1D-0.6%
1W+7.0%
1M+25.3%
3M+14.7%
6M+39.1%
YTD+39.4%
1Y+81.2%
ATR %5.7%
52w lowhigh7.3% off high

What Hansa Biopharma does

Employees: 125

Hansa Biopharma at a glance

Size Hansa Biopharma (HNSA.ST) is a Sweden Health Care company (Pharmaceuticals: Major) with a market value of $479M, the 176th largest of 220 Sweden companies the cockpit tracks. Shares closed at SEK 47.88 on 18 Nov 2026.

Performance Over six months the shares gained 39.1%, against -9.3% for the median peer and +2.8% for the Sweden market (cap-weighted) — 3rd highest of 20 in its peer set.

Growth Revenue grew 68.9% over the last twelve months (peer median +9.4%); the operating margin is -190.3% (peer median 11.2%).

Valuation It trades at 14.9× enterprise value to sales against a peer median of 4.6× (3rd most expensive of 19).

Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +105%, so the hurdle is -110 pp: the price already allows for a slowdown.

Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026HNSA.ST 142Peer median 89
Six months, rebased to 100: Hansa Biopharma against the median of its 20 peers (local-currency closes).

Hansa Biopharma financials

Reported figures in SEK; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueSEK 302MSEK 222MSEK 171MSEK 134MSEK 155M
Revenue growth—+30%+28%-13%—
Gross profitSEK 189MSEK 128MSEK 77.7MSEK 69.3MSEK 116M
EBITDAn/a-SEK 484M-SEK 591M-SEK 780M-SEK 556M
Net income-SEK 800M-SEK 534M-SEK 807M-SEK 832M-SEK 611M
Free cash flowSEK 520M-SEK 549M-SEK 675M-SEK 756M-SEK 506M
Capital expenditureSEK 32.0MSEK 0SEK 116,000SEK 284,000SEK 3.33M
Total debtSEK 948MSEK 939MSEK 1.08BSEK 867MSEK 791M

Quarterly statements and history in the cockpit →

Hansa Biopharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%0%+20%RGNX600624SMSPHARMA688373AQST37050030203012013005843012776620CAPRKPL002107002693AARTIDRUGSHNSA.ST6-month return →1-month return →
Up and to the right = strong over both horizons. Hansa Biopharma is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%+60%0×10×20×RGNX600624SMSPHARMA688373AQST37050030203012013005843012776620EOLS0023701666KPL002693AARTIDRUGSHNSA.STRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Hansa Biopharma is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%370530058430127766201666002693AARTIDRUGSHNSA.STGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Hansa Biopharma is the large dot.

Hansa Biopharma competitors and peer comparison

How Hansa Biopharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hansa Biopharma against its 20 peers (data as of 18 Nov 2026)
MeasureHNSA.STPeer medianRank in peer set
1-month return+25.3%-3.4%2nd highest of 21
6-month return+39.1%-9.3%3rd highest of 20
Distance from 52-week high-7.3%-38.3%4th highest of 21
Revenue growth (TTM)+68.9%+9.4%highest of 20
Operating margin-190.3%11.2%lowest of 19
EV / Sales14.9×4.6×3rd most expensive of 19
Growth the price implies (Req g, 7 yrs)-4.7%7.4%2nd least demanding of 9
Growth delivered (Del g)+105.3%+2.2%2nd highest of 9
Hurdle (Req g minus delivered)-110.0 pp+2.1 ppleast demanding of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Hansa Biopharma HNSA.STSweden$479M+39%+69%-190%14.9×-4.7%+105.3%
REGENXBIO RGNXUnited States$480M+22%-5%-120%3.1×n/an/a
Shanghai Fudan Forward S&T 600624.SSChina$478M0%-14%-34%6.4×n/an/a
SMS Pharmaceuticals SMSPHARMA.NSIndia$477M+16%+13%16%4.9×n/an/a
Shanghai MicuRx Pharmaceutical 688373.SSChina$481M-8%+23%-61%19.0×n/an/a
Aquestive Therapeutics AQSTUnited States$475M-9%+13%-114%10.9×n/an/a
YungShin Global 3705.TWTaiwan$472M+5%-5%15%2.0×-3.8%+0.7%
Hefei Lifeon Pharmaceutical 003020.SZChina$486M-21%-1%10%2.0×n/an/a
ChengDa PharmaCeuticals 301201.SZChina$472M-47%+27%-9%4.8×n/an/a
Nanjing Hicin Pharmaceutical 300584.SZChina$487M-29%+32%17%4.3×3.3%-1.1%
Newland Pharmaceutical 301277.SZChina$488M-22%+9%11%3.5×8.9%+9.1%
Handa Pharmaceuticals 6620.TWOTaiwan$469M+45%-16%30%16.6×24.8%+126.7%
Evolus EOLSUnited States$468M+7%+14%-5%1.8×n/an/a
Zhejiang Yatai Pharmaceutical 002370.SZChina$468M-32%-4%-11%8.8×n/an/a
Tong Ren Tang Technologies 1666.HKHong Kong$491M-19%-14%12%0.6×-17.2%+6.3%
Capricor Therapeutics CAPRUnited States$467M-70%-100%n/an/an/an/a
Kwality Pharmaceuticals KPL.NSIndia$467M+110%+48%22%7.2×n/an/a
Shandong Wohua Pharmaceutical 002107.SZChina$493M-20%-4%18%3.7×5.9%-4.1%
Hainan Shuangcheng Pharmaceuticals 002693.SZChina$465M-28%+40%13%10.8×44.1%+1.0%
Aarti Drugs AARTIDRUGS.NSIndia$494M+34%+15%11%1.8×22.1%+3.5%
BlossomHill Therapeutics BLSMUnited States$464Mn/an/an/an/an/an/a

Questions

Which companies are Hansa Biopharma's closest peers?
The cockpit's peer set: REGENXBIO (RGNX), Shanghai Fudan Forward S&T (600624.SS), SMS Pharmaceuticals (SMSPHARMA.NS), Shanghai MicuRx Pharmaceutical (688373.SS), Aquestive Therapeutics (AQST), YungShin Global (3705.TW), Hefei Lifeon Pharmaceutical (003020.SZ), ChengDa PharmaCeuticals (301201.SZ).
Is Hansa Biopharma expensive compared with its peers?
On ev / sales it trades at 14.9× against a peer median of 4.6×, 3rd most expensive of 19 in its peer set. For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +105%, so the hurdle is -110 pp: the price already allows for a slowdown.
How has Hansa Biopharma stock performed?
Over six months to 18 Nov 2026 the shares returned +39.1% against -9.3% for the median peer; over one year +81.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.